H
Hybridize Therapeutics develops kidney-targeted RNA-based therapeutics designed to protect against acute and chronic kidney diseases. The company utilizes proprietary RNA technology, including chemically modified oligonucleotides, for high target specificity and cell type delivery within the kidney. Their pipeline focuses on developing direct-acting antivirals against polyomaviruses and treatments for Proximal Tubule Epithelial Cell related pathologies.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Hybridize Therapeutics develops kidney-targeted RNA-based therapies for acute and chronic kidney diseases. Their proprietary technology utilizes chemically modified RNA therapeutics coupled with conjugates for highly specific cell delivery within the kidney. The company focuses on protecting the Proximal Tubule Epithelial Cell (PTEC) to prevent disease progression and complications like fibrosis.